drugset / Trial / NCT00456053

A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

NCT00456053 ↗

Phase 2 Completed 145 enrolled Kyntra Bio
RandomizedFactorialSingle-blindTreatment

Summary

The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.

Timeline

Start
2005-12
Primary completion
—
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject FG2216 Unknown — —

Indications